Lantheus (NASDAQ:LNTH) PT Raised to $141.00 at Truist Financial

Lantheus (NASDAQ:LNTH) had its price target hoisted by Truist Financial from $96.00 to $141.00 in a report released on Thursday, Benzinga reports. The brokerage currently has a buy rating on the medical equipment provider’s stock.

Other equities research analysts have also recently issued research reports about the company. B. Riley increased their price target on Lantheus from $95.00 to $99.00 and gave the company a buy rating in a research note on Thursday, April 18th. Mizuho increased their price target on Lantheus from $90.00 to $100.00 and gave the company a buy rating in a research note on Friday, May 3rd. JMP Securities increased their price target on Lantheus from $100.00 to $130.00 and gave the company an outperform rating in a research note on Wednesday. SVB Leerink increased their price target on Lantheus from $106.00 to $127.00 and gave the company an outperform rating in a research note on Thursday. Finally, StockNews.com cut Lantheus from a buy rating to a hold rating in a research note on Friday, May 3rd. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company has an average rating of Moderate Buy and a consensus price target of $113.86.

Lantheus Trading Up 16.4 %

NASDAQ LNTH opened at $123.62 on Thursday. The company has a market cap of $8.57 billion, a PE ratio of 18.87 and a beta of 0.51. The company has a current ratio of 4.84, a quick ratio of 4.55 and a debt-to-equity ratio of 0.59. Lantheus has a 12 month low of $50.20 and a 12 month high of $124.90. The stock has a 50 day moving average of $81.01 and a 200-day moving average of $67.35.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.51 EPS for the quarter, beating the consensus estimate of $1.40 by $0.11. The company had revenue of $369.98 million during the quarter, compared to the consensus estimate of $349.46 million. Lantheus had a return on equity of 54.10% and a net margin of 33.72%. On average, equities research analysts anticipate that Lantheus will post 6.46 EPS for the current fiscal year.

Insiders Place Their Bets

In other Lantheus news, insider Daniel Niedzwiecki sold 12,873 shares of the stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $79.86, for a total transaction of $1,028,037.78. Following the transaction, the insider now owns 80,244 shares in the company, valued at approximately $6,408,285.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CAO Andrea Sabens sold 341 shares of the stock in a transaction on Monday, May 13th. The stock was sold at an average price of $76.89, for a total transaction of $26,219.49. Following the sale, the chief accounting officer now directly owns 62,898 shares of the company’s stock, valued at approximately $4,836,227.22. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Daniel Niedzwiecki sold 12,873 shares of the stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $79.86, for a total value of $1,028,037.78. Following the sale, the insider now directly owns 80,244 shares in the company, valued at $6,408,285.84. The disclosure for this sale can be found here. Insiders have sold 32,269 shares of company stock worth $2,557,300 in the last 90 days. Company insiders own 1.50% of the company’s stock.

Institutional Trading of Lantheus

Large investors have recently modified their holdings of the stock. Clearbridge Investments LLC grew its holdings in shares of Lantheus by 45.4% during the 4th quarter. Clearbridge Investments LLC now owns 538,782 shares of the medical equipment provider’s stock worth $33,404,000 after purchasing an additional 168,114 shares in the last quarter. South Dakota Investment Council boosted its stake in Lantheus by 139.3% in the fourth quarter. South Dakota Investment Council now owns 27,317 shares of the medical equipment provider’s stock valued at $1,694,000 after buying an additional 15,900 shares in the last quarter. Silverberg Bernstein Capital Management LLC acquired a new stake in Lantheus in the fourth quarter valued at about $1,385,000. Boston Partners boosted its stake in Lantheus by 9.6% in the fourth quarter. Boston Partners now owns 562,125 shares of the medical equipment provider’s stock valued at $34,344,000 after buying an additional 49,195 shares in the last quarter. Finally, Commonwealth Equity Services LLC boosted its stake in Lantheus by 23.4% in the first quarter. Commonwealth Equity Services LLC now owns 15,214 shares of the medical equipment provider’s stock valued at $947,000 after buying an additional 2,880 shares in the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.